Stanisic, S., Cicchetti, A., Porta, C., Procopio, G., & Berto, P. (2018). Cost-effectiveness of cabozantinib in second-line treatment of metastatic renal cell cancer (mRCC) in Italy. Global and Regional Health Technology Assessment, 5(1). https://doi.org/10.33393/grhta.2018.434